Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0277787 (
stigma
)
13,352
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dr. Boyd C. Quint recently presented important data regarding the relationship of estrogen therapy to the risk of
endometrial carcinoma
, but the data seem to have been inappropriately analyzed. Dr. Quint studied 291 postmenopausal women who received primary treatment for
endometrial carcinoma
at the Swedish Hospital Medical Center in Seattle, Washington between 1960 and 1973. The 1st step in Quint's analysis was a determination of the ratio of new
endometrial carcinoma
cases to the total "major gynecologic operations" for the intervals 1960-1966 and 1966-1973. This ratio was observed to increase from about 2% for 1960-1966 to about 4% for 1966-1973, but this change -- while statistically significant - cannot be used to support the hypothesis that the absolute incidence of
endometrial carcinoma
increased from the 1st to the 2nd interval. The 2nd step in the analysis was a determination of the incidence of nulliparity, obesity and hypertension, and/or diabetes and prior estrogen therapy among the
endometrial carcinoma
patients 1st treated in each of the 2 intervals. The prevalence of the constitutional
stigma
commonly associated with
endometrial carcinoma
, obesity and hypertension and/or diabetes can be seen to be significantly lower among the 203 patients 1st treated between 1966 and 1973 than among the 88 patients 1st treated between 1960 and 1966. Conversely, the prevalence of prior estrogen therapy is seen to be much higher. Data indicating that approximately 50% of Seattle area women had used or were using estrogen therapy by 1973 to 1974 - median use of about 10 years - are in press. Quint's data do support the hypothesis that estrogen therapy may be an etiologic factor among the more recent cases of
endometrial carcinoma
.
...
PMID:Estrogen therapy and endometrial carcinoma. 98 96
The
stigma
and embarrassment of hirsutism and the lack of public knowledge regarding effective therapy prevent some women from seeking treatment. Heightened physician awareness and a simple, practical approach to the hirsute patient allow adequate assessment and therapeutic recommendations. Decreased hair growth, a return to normal menstrual cycling, and lowered risk of
endometrial cancer
can be achieved by pharmacologic therapy with few serious side effects. Treatment has a significant effect on both physical and mental well-being and can produce a remarkable change in a patient who has suffered embarrassment for many years.
...
PMID:Hirsutism. A practical approach to improving physical and mental well-being. 197 52
Obesity is associated with the development of some of the most prevalent diseases of modern society. The greatest risk is for diabetes mellitus where a body mass index above 35 kg/m2 increases the risk by 93-fold in women and by 42-fold in men. The risk of coronary heart disease is increased 86% by a 20% rise in weight in males, whereas in obese women the risk is increased 3.6-fold. Elevation of blood pressure, hyperlipidaemia and altered haemostatic factors are implicated in this high risk from coronary heart disease. Gallbladder disease is increased 2.7-fold with an enhanced cancer risk especially for colorectal cancer in males and
cancer of the endometrium
and biliary passages in females. Endocrine changes are associated with metabolic diseases and infertility, and respiratory problems result in sleep apnoea, hypoventilation, arrhythmias and eventual cardiac failure. Obesity is not a social
stigma
but an actual disease with a major genetic component to its aetiology and a financial cost estimated at $69 billion for the USA alone.
...
PMID:Obesity as a disease. 924 38